There is also a huge literature on NO releasers as novel antimicrobials [58–60], although little consideration has been given to how NO therapies might impact upon conventional antibiotic treatments, or indeed how iNOS-derived NO might affect antibiotic action at the site of infection. The gene discussed is NOS2; the disease is infection.